BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $600 From $530, Maintains Outperform Rating

BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $600 From $530, Maintains Outperform Rating — alphai